

AUSTRIA

Recent and planned developments in pharmaceutical policies 2017/2018

Special topic: patient involvement in pricing and reimbursement of medicines

CHANGES IN PRICING

Free pricing turns into EU average price reimbursement
medicines outside the <<EKO>>* but financed by social security institutions which reach a turnover of 750,000 Euros (on ex-factory price basis, after 12 months, not calendar year) are reimbursed at EU average price


1

January 2018

CHANGES IN REIMBURSEMENT

2018
Prescription fee 6.00 Euro

OTHER CHANGES



PATIENT INVOLVEMENT IN PRICING AND REIMBURSEMENT OF MEDICINES

For rare diseases but most likely also for other disease areas

WHO	HOW	WHEN	IMPACT
<ul style="list-style-type: none"> •Patient organisations •Head physician at MASSi 	<ul style="list-style-type: none"> •personal meetings on appointment 	<ul style="list-style-type: none"> •case-by-case basis •medicines already on the market 	<ul style="list-style-type: none"> •unclear

no involvement of patients in HTA



Hauptverband der österreichischen Sozialversicherungsträger

Although patients are not directly systematically involved, representatives of consumer interests are involved in committees with regard to pricing (Preiskommission at the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection) and reimbursement (Heilmittelbewertungskommission at the Main Association of Social Security Institutions) decisions.